My on-the-ground DD in Shanghai seems to indicate that NQ does't generate substantial revenue. The few people who knew about NQ said they weren't doing great as most Chinese smartphone users have 360Guardian on their phone, not NQ, why? 360Guardian is much more well known and is free. take a look at 360 dot cn. Log on to any PC in China, you will see it's protected by 360, same as on smartphone.
There was 1 comment made by 1 friend who also works in the Chinese smartphone app field that really shocked me. He said he was familiar with NQ and it's headquartered in TianJin and YiDaTong is just a front for money-laundering. I always thought NQ was headquartered in Beijing, but I dug deeper and now believe he indeed knew NQ. But this is just 1 guy. But he is a friend and has no reason to BS me.
Logical and well said. The current price presents a once-in-a-year buying opportunity. I have no doubt the price will be $50 when Adcom rolls around mid-2015.
The events that have been unfolding lately should make anyone who is at least somewhat objective to realize that NQ management is not forthcoming and there is no upside to the stock in the near future. I just came back my trip to China and I did some basic DD while there. I went to 3 major computer/electronics malls in Shanghai and asked every other vendor in the mall and only 1 out of 10 even heard of NetQin. None of the smartphones I saw for sale has NQ software preloaded. Samsung, huaWei, Mi, you name it. None. I was surprised. I expected to see some market share but none.
Longs, you need to wake up. Besides some deadcat bounces, there will be no upside in staying in NQ. Get out while you still can. This can still go lower.
That's a lot of words that really mean nothing.
I will share something short and meaningful with you: 144-week data will be fantastic. Several boys have already done the testing and results are great. So the only question is how do you plan to profit on this information?
If I were you, I will sell a ton of July puts to finance buy of tons of Aug calls. But to each his own. GLTA.
RMTI has a pattern of drifting towards $10 after each and every good news. Any spike caused by good news has been short lived. This may be a reflection of market's uncertainty towards Triferic's commercial potential. So last Friday is the expected first major down turn from the high 11s we have enjoyed since the NDA acceptance news. I expect to see a few more major downturns between now and June opex to get the price down to $10 +- 10c. Biotech has been on a tear for over a week. It's time for a pullback. RMTI also has hit the upper end of the bollinger band and the pullback is expected.
The only thing that can stop this down drift is Calcitriol NDA approval, but that probably will not happen for another 2-3 months.
Just my 2 cents and GLTY.
Data will be out in June, IMO.
This stock has been manipulated like a yoyo. The last 30 mins of today was a true roller coaster. The fact small bio have been up for 5 consecutive days means we will likely to trade lower next week. Coupled with the fact we closed at LoD, I expect to see mid-10 next week and even lower-10 getting to June expiry. Another reason for possible downtrend, there is no near term catalyst in $RMTI.
2015 and 2016 are leaps. Regular options will show up once time comes. Why do you want to trade in middle of 2015 NOW? If you want to buy for NDA approval, I suggest you buy 2016.
Same here: 6000 shares under $10 and have been selling calls at 10,11,12 for 3 months. I also sell naked higher OTM calls when stock spikes like we saw 2 weeks before May expiry. Couldn't be happier.
Yes, it's true FDA acceptance decision happens at 60 days. However, there is virtually no upside to the acceptance, only downside. Acceptance is generally expected unless you truly screwed up. Occasionally, NDA will be rejected due to inexperienced sponsor. One notable case is DCTH's RTF decision, which caused the company dearly.
If anything, I expect to see downward pressure as investor hedge to the downside. If there is any price spike, one will do well selling into it.
I saw the same thing on twitter. The rehab doctor was in "shock and awe" with regards to Billy's measurements.
Anyone who has been half paying attention will know 144 wk data will be out 24 wks after 120 wks data, which was release on Jan 15th. So give or take a week or so, 144 wk will be release around July 15th.
If you don't know this, then you probably should not invest in SRPT.
I have been in SRPT much longer than you. So don't lecture me on the potential of price appreciation. You are one of those mindless pumpers I had in mind when I wrote my original post. All you have is hope and more hope. The hallmark of people like you is coming up with a price target that has no details backing them and spreading unsubstantiated rumor about buyout. Quit it!
Yes, I would exercise Jan 2015 ITM calls to cover the weekly options. Remember, I'm selling weekly volatility and if called away, I will still be profitable in the trade.
As a rule of thumb, I sell volatility when it's high(weekly volatility is very high) and buy volatility when it's low(deep ITM leaps have very low volatility at this time).
Make no mistake. SRPT will continue to be very volatile. It will not surprise me that we close the gap all the way to $27 between now and 144 wk data. However, if you understand the science and the sales potential, then you should have no fear if/when that happens. On the other hand, don't listen to pumpers who claims $40, $50 in the next week or 2 and if you hang your hopes on these short term pumped up price targets, you will get hurt.
For me, I have a core position in Jan 2015 deep ITM calls and have picked up a bit more last week during the trip to $30. On the other hand, I continue to sell OTM front-week calls when there is a uptrend.
Remember Mr. Market's job is to allow fewest investors to be profitable and investing in small cap biotech is extremely dangerous and inherently high beta. With that said, I'm convinced that SRPT is the leader in RNA technology and is sitting on a gold mine on their research platform. I fully expect a 500% ROI in 3-5 years.